• Natasha Ali Aga Khan University, Karachi
  • Mohammad Khurshid Aga Khan University, Karachi




Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- hodgkin’s lymphoma. N Engl J Med 1995;333:1540-5.

Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate- grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987;316:1493-8.

Pervez S. Non-hodgkin lymphoma (NHL) in Pakistan. Int J Mol Cell Med 2012;1:62-3.

Ali N, Adil SN, Shaikh MU. Autologous hematopoietic stem cell transplantation-10 years of data from a developing country. Stem Cells Transl Med 2015;4:873-7.

Philip T, Hartmann O, Biron P, et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin’s lymphoma. J Clin Oncol 1988;6:1118-24.

Santini G, Congiu AM, Coser P, et al. Autologous bone marrow transplantation in 100 cases of poor- prognosis non-Hodgkin’s lymphoma. A report of the Non-Hodgkin’s lymphoma cooperative study group. In: Dicke KA, Keating A, editors. Autologous Bone Marrow Transplantation. Arlington (Texas): Proceeding of the Sixth International Symposium; 1993. p. 75-82.

Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:1729-36.

Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012;30:4462-9.

Zhang W, Jiao L, Zhou DB, et al. Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Oncol Lett 2010;1:733-8.

Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006;12:1065-72.

Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 2010;28:5074-80.

Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848 54.

Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9.

Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: The German Hodgkin study group experience. Blood 2012;120:1470-2.

Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2013;54:2144-8.

How to Cite
Ali N, Khurshid M. AUTOLOGOUS TRANSPLANT IN LYMPHOMAS IN CURRENT ERA OF IMMUNOTHERAPY. J Cancer Allied Spec [Internet]. 2016Dec.31 [cited 2020Aug.15];2(4). Available from: